Trial Profile
The efficacy of eicosapentaenoic acid on glucose variability for type 2 diabetes mellitus: randomized controlled trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2018
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Hyperlipidaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Oct 2018 Status changed from recruiting to discontinued.
- 29 Sep 2017 New trial record